returned to dialysis. The linear expansion rate of the Background. The new Centre Questionnaire, mainly dialysis pool and the transplant pool was respectively based on the collection of epidemiological data, was 8.3% and 7.9%. launched in 1996 and the overall response rate of Conclusions. This data shows considerable disparities centres for the 15 countries constituting the European among countries of the EU which merit further evaluUnion ( EU ) reached 82.2% (66-100%) for 1995.
Epidemiology of treated ESRF in Europe during 1995 Europe during 2333 to a 100% RR. In this calculation, we have assumed that the are financial constraints on the use of renal replacement populations surveyed in the different centres (big, medium, therapy (RRT ) with the risk of suitable patients failing small ) were homogeneous within a country but, of course, we to receive treatment.
cannot be certain that this is so. However, we have shown
In this paper, we present the 1995 epidemiological that the size of the centres (i.e. number of patients) was data on patients treated for ESRF in Europe by all independent of the response rates in the reports to our registry. available modalities of treatment. The information is The accuracy of these estimates was directly correlated to the not complete for all countries, which limits the validity RR: fair between 60% and 74%; good between 75% and 89%; and value of the data. However, for the European excellent between 90% and 99%; and perfect for 100%. Union ( EU ), formerly called the European Economic Community ( EEC ), the data is now much more com-Epidemiology of treated ESRF in 1995 plete and we have therefore focused on the EU countries in this analysis. The EU currently comprises The analysis was done according to a single-compartment 15 countries: Austria, Belgium, Denmark, Finland, as previously published (Figure 1) . France, Germany, Greece, Ireland, Italy, Luxembourg, $ Ni (i for input) is the number of new ESRD patients who
The Netherlands, Portugal, Spain, Sweden and United started their first RRT in 1995.
Kingdom ( UK ).
$ No (o for output) is the number of ESRD patients (any year of start) who died during 1995. $ Ns (s for stock) is the number of ESRD patients on RRT
Material and methods
alive on 31 December 1995. $ P is the general population of the country in the middle The European Dialysis and Transplant Association ( EDTA) of 1995, expressed in millions of population. Registry was created three decades ago for the purpose of From these numbers, we derived: evaluating ESRF and its treatment. In the last decade, several factors contributed to a decrease in the performance of this $ the incidence of ESRF: Ni/P expressed per million popularegistry. These included an increase in the number of dialysis tion per year (p.m.p.); and transplant centres, an increase in the number of patients $ the incidence of ESRF deaths: No/P p.m.p.; on treatment, lack of specific support for filling in patient $ the point prevalence of ESRF (treated alive): Ns/P p.m.p.; questionnaires, failure of adaptation to the progress of $ the number of new patients expressed as % of the ESRF computer science, and lack of regular feedback of data. At pool: Ki=Ni/Ns; the same time, the association extended its activity to general $ the number of deaths expressed as % of the ESRF pool: nephrology and became the European Renal Association Ko=No/Ns; (ERA) and the registry became the ERA Registry. As a $ the net increase in ESRF patients: (Ni-No)/P p.m.p.; result of the poor response rate to the Patient Questionnaires $ the linear expansion rate of the ESRF pool: Ki-Ko= (PQ), the ERA Registry was completely reorganized [1] [2] [3] .
(Ni-No)/Ns; In addition, a new Centre Questionnaire (CQ) was launched $ the fractional expansion rate of the ESRF pool (exponento collect epidemiological data on a yearly basis, starting tial ): Ns(1995)=Ns(1994) exp (+Kt) with t=1 year and from the year 1995. The analysis by country of the results Ns(1994 )=Ns(1995 ; K=Log [Ns(95)/ of the 1995 CQ is presented in this manuscript.
Ns (94)]. This fractional rate should be used to make This CQ was sent to all dialysis and transplant centres predictions for following years. known to the registry, either directly or through regional or national registries. The following questions were asked: number of new patients starting their first RRT in the year; modality of first RRT; number of ESRF patients dying during the year with modality of RRT at time of death; number of ESRF patients alive on 31 December and the modality of treatment; number of dialysed patients receiving a renal Tx during the year; number of transplanted patients returning to dialysis during the year.
Adjustment of data according to response rate
The general population surveyed by the centres was, in general, greatly overestimated by them. In the case of 100% response rate (RR), the general population of the country was taken as that for mid-1995. All these populations were obtained from 1995 World Population Data Sheet (Population Reference Bureau Inc, Washington DC, USA).
Until now, the ERA Registry has only published reported treated ESRF and due to the low response rate, the numbers published have been a considerable underestimate. For this Fig. 1 . The Single-Compartment Model. The ESRF patients alive analysis, we decided to publish only data for countries with a on 31 December are considered as a single pool whose size correresponse rate of at least 60%, which was arbitrarily chosen sponds to the number of patients Ns (in stock). New patients (Ni) and which in the future will be increased to 75% or higher. are entering the pool and dead patients (No) are leaving the pool In order to estimate the true numbers for countries with RR with generation of inflow ( Ki) and outflow ( Ko). The pool size is following an exponential rate, K=Ki-Ko. between 60% and 99%, we extrapolated the reported numbers $ KoD=NoD/ NsD; death rate of dialysed patients.
Epidemiology of treated ESRF in 1995 by dialysis (D)
$ KDTx=NDTx/NsD; the rate of transplantation for dia- 
Epidemiology of treated ESRF by HD or PD
For new patients, the first RRT was HD(NiHD) or PD(NiPD) or pre-emptive Tx(NiTx) with Ni=NiHD+ NiPD+NiTx and NiD=NiHD+NiPD. For patients dying during the year, the last RRT was HD(NoHD) or PD(NoPD) or Tx (NoTx) with No= NoHD+NoPD + NoTx and NoD=NoHD+NoPD.
For living ESRF patients, the RRT on 31 December was HD(NsHD) or PD (NsPD) or Tx(NsTx) with Ns= NsHD+NsPD+NsTx and NsD=NsHD+NsPD. to the modality of ESRF treatment: the dialysed pool (NsD) and the transplanted pool (NsTx). New patients are entering both pools We have analysed the 15 countries constituting the EU (NiD and NiTx) but mainly the dialysed pool. Dead patients are (ex-EEC ). The numbers obtained for each country were leaving both pools (NoD and NoTx). In addition, there are bilateral added up and the total numbers were considered as for a transfers between the two pools (NDTx and NTxD). All these unique entity, with secondary calculations of the different different flows can be calculated using either a linear or an exponential rate. characteristics of this entity.
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The different utilization of dialysis treatment modalities
Results in the EU during 1995: HD vs PD Epidemiology of ESRF in the EU for 1995
The results are given in Table III and Table IV to 89.0% in Portugal ), PD in 9.0% (ranging from 1.6% The flow rate of new ESRF patients represented in Portugal to 21.1% in UK ) and a functioning Tx in 18.6% of the total pool with values from 10.8% in 32.5% (ranging from 9.4% in Portugal to 78.6% in Ireland to 25.1% in Luxembourg (column 11). The Ireland ). death rate among treated ESRF patients was 10.4%
The mean death rate was 13.4% for HD (ranging ranging from 5.4% in Ireland to 12.6% in denmark from 9.6% in Greece to 29.8% in Ireland ) as compared (column 12). The ESRF pool linear expansion rate to 20.7% for PD (ranging from 6.9% in Ireland to was 8.2% with values from 4.6% in Finland to 13.0% 39.7% in Greece). However, these death rates cannot in Luxembourg (column 13). The ESRF pool frac-be interpreted without correction for age and the length tional expansion rate was 0.085 with range from 0.023 of time on treatment. in Greece to 0.139 in Luxembourg (column 14).
Epidemiology of treated ESRF by Tx in the EU for 1995
The results are given in of 82.2%. This RR was fair for three countries ( France, Portugal, Spain); good for four countries (Germany, Ireland, Sweden, UK ); excellent for three countries (Austria, Greece, Italy) and perfect for five countries (Belgium, Denmark, Finland, Luxembourg, Netherlands) with national registries [7, 8] .
For the first time, our registry, in collaboration with national registries has been able to publish fairly complete data on the epidemiology of ESRF and its treatment by HD, PD and Tx with an estimate of all treated patients and not only reported patients. This is the start of an annual production of new epidemiological data, but we hope to be faster in the future.
Content of the data
This large set of data shows many variations between countries which have a fairly similar economic background. Thus at least some of the differences may not be due to strategic differences in health programmes but to different epidemiological characteristics. Such disparities may also exist within the countries and in the future, the national registries will be able to further study these regional differences. At the level of our registry, it will be our task to clarify and explain the differences between countries and this will only be possible by closer cooperation and exchange of information with the national registries. For these reasons, we are encouraging the development of both national and regional registries.
An example of the differences between countries is the incidence of ESRF which is 120 p.m.p. for whole EU. However, there is clearly a north to south/west gradient with countries belonging to northern Europe such as Denmark, Finland, Ireland, Sweden and the UK having the lowest values (from 68 to 99) while the countries of southern Europe (Italy, Portugal, Spain) exhibiting higher values (from 121 to 131) and those of western Europe (Belgium, France, Luxembourg, Netherlands) having intermediate values (from 82 to 155) except for Germany (163). One can only speculate whether these differences are due to the age distribution of the population (9) or other factors and further studies are required to address these issues. One of the limitation of the CQ, is the absence of information on gender and age of the patients (for new patients, a/o dead patients, a/o treated alive patients) which does not permit the adjustements of basic epidemiological information (incidence, prevalence, etc.) and further comparisons between countries.
Treatment of ESRF in 1995
The data also show variations among countries in the use of available modalities of treatment, which could be explained by different economic policies. Nevertheless, the different cultures and the different medical approaches could also be important explanations. These different points also need to be addressed by specific studies. For example, PD is well accepted as first line treatment in northern Europe with up to 30% of patients receiving this treatment in Denmark, All these data are shown in Table VI . It is interesting to note that the ESRF linear expansion rate is very Finland, Sweden and UK. This is in contrast to Germany (10%), Spain (13%), Belgium (6%) and similar in all countries (from 6.6 to 8.2%). Austria (8%).
Along the same lines, renal Tx is more widely used
Conclusion
in Northern Europe and a few countries achieve more than 50% of all ESRF patients with a functioning graft e.g. Ireland with 78.6%, Finland (61.8%), UK (51.9%), We have presented in this analysis an accurate estimate Sweden (52.7%) and The Netherlands (50.1%). The of the 1995 epidemiology of ESRF in the 15 countries economic savings resulting from the widespread use of constituting our current EU. Tx in these countries is potentially considerable.
Comparisons inside and outside Europe clearly raise many interesting questions to be solved in the future by multinational epidemiological studies.
Modelling of ESRF epidemiology and treatment
In the future the ERA Registry will seek to work in In this paper, we have presented simple data with closer collaboration with the national and regional analysis according to compartment modelling [5] . For registries within Europe and also with the other intersimplicity, we have used the linear rates, but for future national registries. prediction we should use the constant fractional rates (exponential analysis). We have so far restricted the presentation to K expon, KD expon and KTx expon. References
Other predictive methods have been proposed and
